SHALCIP

This brand name is authorized in Nigeria.

Active ingredients

The drug SHALCIP contains one active pharmaceutical ingredient (API):

1	Ciprofloxacin UNII 5E8K9I0O4U - CIPROFLOXACIN
	Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
	Read more about Ciprofloxacin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-6073	Intravenous infusion	Shalcip Infusion INJ_SOL 200 mg	SHALCIP INFUSION A4-6073 SHALCIP INFUSION Ciprofloxacin USP 200mg, Sodium Chloride USP 900g Lactic acid, Disodium EDTA, Hydrochloric acid, Sodium Hydroxide, Water for injections Intravenous Infusion Prescription Only Medicine (POM) SHALINA HEALTHCARE NIGERIA LIMITED, FATAI ATERE WAY, MATORI MUSHIN LAGOS LAGOS Nigeria Fresenius Kabi India Private Limited, Plot No. A/3, MIDC Ranjangaon anpati, Tal. Shirur, Pune 412220 Maharashtra State. India, India 26/01/2023 25/01/2028	26/01/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA02	Ciprofloxacin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-6073